Kazia Therapeutics (KZIA) & Its Rivals Critical Analysis

Kazia Therapeutics (NASDAQ: KZIA) is one of 526 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Kazia Therapeutics to related businesses based on the strength of its analyst recommendations, dividends, risk, earnings, institutional ownership, profitability and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Kazia Therapeutics and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kazia Therapeutics 0 0 0 0 N/A
Kazia Therapeutics Competitors 3699 10843 24773 812 2.57

As a group, “Pharmaceutical preparations” companies have a potential upside of 57.50%. Given Kazia Therapeutics’ competitors higher possible upside, analysts clearly believe Kazia Therapeutics has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares Kazia Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Kazia Therapeutics $90,000.00 -$4.68 million N/A
Kazia Therapeutics Competitors $1.95 billion $126.73 million -8.09

Kazia Therapeutics’ competitors have higher revenue and earnings than Kazia Therapeutics.

Risk & Volatility

Kazia Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Comparatively, Kazia Therapeutics’ competitors have a beta of 0.94, suggesting that their average share price is 6% less volatile than the S&P 500.

Profitability

This table compares Kazia Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kazia Therapeutics N/A N/A N/A
Kazia Therapeutics Competitors -2,656.27% -68.46% -24.43%

Institutional & Insider Ownership

2.2% of Kazia Therapeutics shares are held by institutional investors. Comparatively, 46.2% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 1.0% of Kazia Therapeutics shares are held by insiders. Comparatively, 15.3% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Kazia Therapeutics competitors beat Kazia Therapeutics on 5 of the 9 factors compared.

Kazia Therapeutics Company Profile

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer. It has collaboration agreements with The University of York, The Children's Cancer Institute Australia, The Mater Institute in Queensland, the University of Boston, and St Jude Children's Research Hospital. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Receive News & Ratings for Kazia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kazia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply